The 11th European Stroke Organisation Conference (ESOC 2025) took place from 21st-23rd May 2025 at the Messukeskus Helsinki Expo and Convention Centre in Finland. The event attracted over 4,200 participants from 96 countries, featuring 288 faculty speakers, 48 exhibitors, and nearly 2,100 submitted abstracts—reflecting its position as Europe’s premier forum for advancing cerebrovascular disease care.
This report includes key clinical and research highlights from ESOC 2025, offering insights designed to inform practice, drive innovation, and support future stroke policy development.
Clinical trial results and research highlights
The European Stroke Organisation Conference (ESOC) 2025 in Helsinki delivered a breadth of new trial data, reflecting progress across acute interventions, prevention, rehabilitation, and health systems.
Day 1 opened with practice-changing insights. A study on combined oral contraceptives reported a tripling of cryptogenic stroke risk in young women, sharpening awareness of sex-specific risk factors. Lifestyle prevention was reinforced by the ARIC study, which linked regular oral care to reduced stroke risk. Acute management featured prominently: the BRIDGE TNK trial confirmed the benefit of adding intravenous tenecteplase before thrombectomy, while a sub-analysis of DISTAL and post-hoc results from ESCAPE-MeVO refined imaging-based selection for endovascular therapy in medium-vessel occlusions. Meanwhile, the ASSET-IT trial of tirofiban after thrombolysis showed functional gains but with excess bleeding, underlining the risk–benefit balance in adjunct antiplatelet therapy.
A major highlight of the day was the presentation of the OPTIMIST main trial, a large multicentre study comparing less-intensity with standard high-intensity monitoring after intravenous thrombolysis in mild to moderate ischaemic stroke. The trial found no difference in functional outcomes at 90 days, confirming the non-inferiority and safety of low-intensity monitoring. Importantly, this approach was well accepted by patients, nurses, and clinicians, while potentially reducing ICU use and associated costs. The results support adapting scalable monitoring protocols to optimise hospital resources and streamline post-thrombolysis care, marking an important step toward more efficient, patient-centred stroke management. In secondary prevention, the EXCOA-CVT trial found no benefit of extended anticoagulation in cerebral venous thrombosis, while several rehabilitation studies – including HOME-Rehab, StroCare, and LAST-long – questioned assumptions about home visits and structured care but highlighted the promise of coordinated follow-up.
Day 2 shifted to innovation and global perspectives. The landmark GOLDEN BRIDGE II trial showed that integrating an AI-driven clinical decision support system into acute stroke care improved adherence to evidence-based protocols and reduced recurrent events and mortality in over 21,000 patients. In resource-limited settings, the PINGS-II trial demonstrated that nurse-led, phone-based hypertension management in Ghana significantly improved outcomes, offering a scalable model for low- and middle-income countries. Preventive focus deepened with the DEMDAS study, which identified metabolic syndrome as a major modifiable risk factor for post-stroke dementia, while the ESTREL trial tempered enthusiasm for levodopa as an adjunct in rehabilitation.
Day 3 highlighted prehospital and inflammatory strategies. The MSU-TELEMED trial validated remote neurologist assessment on mobile stroke units as safe and efficient, and the MAP-STROKE algorithm showed potential to streamline hospital triage. Inflammation-targeted therapies gained momentum: the CoVasc-ICH trial established the feasibility of colchicine in intracerebral haemorrhage, while a new CONVINCE analysis linked reduced CRP suppression with fewer recurrent events after ischaemic stroke. The IRIS trial provided further promise for interleukin-6 receptor inhibition in patients undergoing endovascular therapy. Finally, secondary prevention advanced with OPTIMAS, which confirmed that early DOAC initiation is safe even in the presence of large infarcts or haemorrhagic transformation.
Table summarising the key ESOC 2025 trials, interventions, and main outcomes.
| Trial / Study | Population / Setting | Intervention / Focus | Key Findings / Outcome |
| BRIDGE TNK | Acute ischaemic stroke, large vessel occlusion | Tenecteplase bridging + thrombectomy | Improved functional outcomes vs thrombectomy alone; potential new standard |
| DISTAL (sub-analysis) | Medium distal vessel occlusion | Endovascular therapy (EVT) | Preserved more brain tissue vs best medical therapy |
| ESCAPE-MeVO (post-hoc) | Medium vessel occlusion | EVT guided by imaging | Collateral status on CT angiography strongest predictor of 90-day outcome |
| ASSET-IT | Post-IV thrombolysis stroke patients, China | Tirofiban adjunct | Improved functional outcomes, increased intracranial bleeding |
| MSU-TELEMED | Mobile stroke unit patients | Tele-neurology assessment | Safe, more resource-efficient than onboard neurologist model |
| MAP-STROKE algorithm | Prehospital triage | Ambulance decision support | Optimised hospital routing, accelerated treatment |
| EXCOA-CVT | Cerebral vein thrombosis | Extended anticoagulation | No clear benefit; supports individualised approach |
| OPTIMAS | Post-ischaemic stroke | Early DOAC initiation | Safe and non-inferior to delayed initiation |
| CONVINCE (CRP analysis) | Ischaemic stroke | Long-term colchicine | Low CRP linked to fewer recurrent vascular events |
| CoVasc-ICH (Phase 2) | Intracerebral haemorrhage | Colchicine | Feasible and safe; Phase 3 underway |
| GOLDEN BRIDGE II | GOLDEN BRIDGE II Acute ischaemic stroke, >21,600 patients, China | AI clinical decision support system (CDSS) | Improved adherence to protocols, reduced recurrent events and mortality at 1 year |
| PINGS-II | Stroke survivors, Ghana | Nurse-led phone intervention | Improved blood pressure control; scalable for low-resource settings |
| DEMDAS | Stroke survivors, multi-centre cohort | Observational | Metabolic syndrome strongly linked to delayed-onset post-stroke dementia |
| ESTREL | Post-stroke rehabilitation, Switzerland | Levodopa adjunct therapy | No additional benefit on functional motor outcomes |
| HOME-Rehab | Post-stroke patients | Home visits vs in-hospital discharge planning | No measurable benefit; informs resource allocation |
| StroCare | Post-stroke coordinated care | Structured follow-up | Improved patient reassurance and engagement; primary outcomes mixed |
| LAST-long | Long-term post-stroke support | Coordinator-led follow-up | Feasible; supports structured long-term care models |
| EECP trial | Symptomatic severe intracranial stenosis | Enhanced external counterpulsation | Improved cerebral haemodynamic, potential stroke recurrence reduction |
| IRIS | AIS undergoing EVT | IL-6 receptor inhibition | Phase 2 evidence suggests improved outcomes, anti-inflammatory strategy |
| CERES-TANDEM | Tandem-lesion stroke, >4,000 patients | Emergent carotid stenting + EVT | Safe, improved 90-day functional outcomes |
| DETERMINE | Anterior LVO stroke | Individualised BP management during MT | No benefit over standard BP approach |
Interesting workshop/session: The CSVD session highlighted mechanisms, clinical consequences, and emerging therapies for cerebral small vessel disease.
Summary table:
| Speaker | Topic / Focus | Key Points / Findings | Clinical Implications |
| Prof. Alastair Webb (UK) | Regulation of cerebral blood flow and CSVD development | Blood pressure variability is a causal factor; stable cerebral perfusion is critical to prevent white matter damage | Highlights importance of blood pressure management to slow CSVD progression |
| Prof. Geert Jan Biessels (Netherlands) | Cognitive performance prediction in CSVD | Lesion topography better predicts cognitive impairment than total burden; meta-VCI maps and disconnectome analyses link subcortical lesions to domain-specific deficits | Provides tools for personalised assessment of cognitive risk in CSVD patients |
| Prof. Alexandros Polymeris (Switzerland) | CSVD in patients with atrial fibrillation | AF associated with increased white matter changes and biomarkers of neuronal injury; anticoagulation remains indicated despite haemorrhagic risk | Supports continuing anticoagulation while considering CSVD features for individualised therapy |
| Prof. Fran-Erik De Leeuw (Netherlands) | Vascular cognitive impairment due to SVD | Early prevention, especially blood pressure control in younger adults, preserves brain resilience; slow, variable clinical course of SVD | Emphasises targeting younger populations for intervention to prevent cognitive decline |
| Prof. Joanna Wardlaw (UK) | Role of cilostazol in SVD | CSVD is modifiable; early intervention, precise imaging, and targeted therapies are key | Potential disease-modifying therapy for CSVD, particularly for secondary stroke prevention |
| Overall, Session Message | CSVD mechanisms, outcomes, and therapies | CSVD is modifiable; early intervention, precise imaging, and targeted therapies are key | Prevention and personalised care are essential to reduce stroke and vascular cognitive impairment |
Emerging topics and future directions
ESOC Helsinki 2025 spotlighted cutting-edge advancements in digital health and AI, highlighting their potential in diagnostics, personalised therapy, and remote patient monitoring. Sessions illustrated AI-driven imaging analysis, predictive algorithms, and telehealth integration as tools to enhance clinical decision-making. There was focus on health equity, global perspectives, and multidisciplinary care, with strategies to reduce disparities in access and outcomes across diverse populations. Innovations in training and education, included virtual reality simulations, interactive e-learning, and patient engagement platforms. Looking beyond 2025, the field appears poised for deeper integration of AI-assisted clinical workflows, global collaborations, and patient-centred models that combine technology, data, and multidisciplinary expertise to optimise care delivery worldwide.
ESOC Helsinki 2025 offered an exclusive dynamic in person experience by fostering networking through interactive workshops, roundtable discussions, and young investigator sessions, creating opportunities for early-career researchers to engage with established experts. Oral and poster presentations played a vital role in showcasing the latest scientific advances, encouraging the exchange of innovative ideas, and providing a platform for emerging researchers to share their findings with the global stroke community. Patient advocacy and public health discussions highlighted patient voices in shaping research and clinical priorities. International collaboration was a key highlight, reinforcing ESOC’s commitment to a global, multidisciplinary approach. The combination of scientific rigor, hands-on learning, and community engagement—enriched by the high-quality poster and abstract sessions—contributed to a stimulating and inclusive conference environment.
Conclusion
ESOC Helsinki 2025 underscored the pivotal role of technology, equity, and collaborative care in redefining the future of stroke care. Central themes included the integration of AI into clinical practice, the drive to reduce health disparities, and the advancement of multidisciplinary, patient-centred models. Cutting-edge sessions showcased AI-driven diagnostics, predictive analytics, telehealth, and personalised therapies, while innovations in medical education and patient engagement—such as VR simulations and interactive e-learning—reflected the evolution of training and teamwork in healthcare.
The in-person format sparked lively interaction through workshops, young investigator sessions, and networking events. Patient advocacy and global collaboration strengthened ESOC’s role as a hub for inclusive, forward-looking dialogue.
In summary, ESOC 2025 set a clear trajectory toward AI-assisted workflows, integrated global partnerships, and patient-empowered systems of care—momentum that will carry forward to ESOC 2026 in Maastricht, driving the next wave of innovation in digital stroke health.
